Mandate

Vinge advises Cellink in conjunction with the acquisition of cytena

August 05, 2019 M&A

Vinge has advised Cellink AB (publ) in connection with the acquisition of all shares in cytena GmbH. cytena is a life science company which focuses on single cell technologies.

Cytena was established in 2014 from the Institute for Microsystems Technology at the University of Freiburg and primarily sells solutions for the handling of biological cells. The purchase price amounts to MEUR 30.25, corresponding to MSEK 323, and is paid with 1/3 in cash and 2/3 in newly issued Cellink shares. Cellink will convene an extraordinary general meeting which will resolve upon the directed issue of shares to the sellers of cytena.

Vinge’s team primarily consisted of Anders Strid, Daniel Lennartsson Anderås, Alexander Lindeberg and Adam Loewenstein.

Related

Vinge advises Isofol Medical AB (publ) in connection with its rights issue of units

Through the rights issue of units, consisting of shares and warrants, and the exercised over-allotment issue, Isofol will receive approximately SEK 84 million and may receive an additional maximum of approximately SEK 110 million upon exercise of all warrants at the highest subscription price.
August 01, 2025

Vinge advises Oncorena in connection with share issue

Vinge advises Oncorena Holding AB in connection with a share issue of approximately SEK 133 million.
July 30, 2025

Vinge advises Karl Hedin and minority owners on the sale of AB Karl Hedin Sågverk to Vida

Vinge has advised Karl Hedin and minority shareholders in connection with the sale of AB Karl Hedin Sågverk to Vida Aktiebolag (“Vida”).
July 24, 2025